STAT3 and myelofibrosis: We have previously reported that pacritinib displays more favorable pharmacokinetic properties in humans than in mice.18 Pacritinib has completed a phase III trial for myelofibrosis, with daily oral dosing, and has demonstrated promising pharmacokinetic and safety profiles with limited toxicities in humans.38 It would also be of high clinical relevance to further investigate other JAK/STAT3 inhibitors, existing or currently under development, in combinatorial studies with brain-penetrant EGFR inhibitors such as afatinib.